Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 03 January 2013 | By Louise Zornoza
Brazil's National Health Surveillance Agency, Anvisa, has released a notice clarifying the rights of individuals who participate as clinical research subjects in the country.
The notice specifies that clinical trial subjects must be informed that Brazilian law prohibits compensation for participating in a trial with the exception of being reimbursed for the cost of transportation and meals. The notice also states that a clinical trial subject has the right to leave a study at any time-even after informed consent has been obtained-and this right must also be specified in the informed consent document.
Anvisa also explained that it screens proposed clinical trials for compliance with Good Clinical Practice (GCP) requirements and conducts inspections of Brazilian research centers to verify adherence to those requirements. Further, the agency calls on the public to directly notify the Research Ethics Committee of the Research Center and the National Committee for Research Ethics regarding any violations of the rights of clinical trial subjects. Complaints may also be notified to Anvisa through its Call Center or through the agency's website.
Read more:
Read all Breaking News from RegLink
Tags: Informed Consent, Payment, Latest News, compensation, brazil, clinical trials, GCP